Ligand Pharmaceuticals vs Schrodinger
LGND and SDGR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LGND and SDGR compare
Ligand Pharmaceuticals is the larger company, worth 2.7 times as much as Schrodinger ($6.3B against $2.4B).
Schrodinger grew revenue faster over the last twelve months (4.8% versus 1.0% for Ligand Pharmaceuticals).
Ligand Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 20.3% compared with −22.0% at Schrodinger.
Schrodinger scores higher on the StockData Score (12 against 6 for Ligand Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LGND | SDGR |
|---|---|---|
| Size and price | ||
| Market cap | $6.3B | $2.4B |
| Share price | $316.83 | $31.52 |
| Change, 1 year | 51.4% | 72.3% |
| Change, 5 years | 95.7% | −22.7% |
| Beta (5Y) | 1.30 | 1.85 |
| Employees | 47 | 850 |
| StockData Score | ||
| Total score | 6 | 12 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 3 | 3 |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 138× | – |
| P/S | 25.0× | 8.8× (better) |
| P/B | 6.6× (better) | 7.8× |
| EV/EBITDA | 116× | – |
| P/FCF | 69.9× | – |
| FCF yield | 1.4% (better) | −5.0% |
| Fair value | $55.98 | $17.66 |
| Margin of safety | −466% | −78.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 1.0% | 4.8% (better) |
| Revenue growth, 5Y average | 10.4% | 18.8% (better) |
| Net income growth (TTM) | 5.9% | – |
| EPS growth (TTM) | 18.7% | – |
| Profitability | ||
| Gross margin | – | 58.5% |
| Operating margin | 10.1% (better) | −49.6% |
| Net margin | 20.3% (better) | −22.0% |
| FCF margin | 35.7% (better) | −43.4% |
| Return on equity | 5.4% (better) | −19.0% |
| Return on invested capital | 2.6% | – |
| Financial health | ||
| Debt / equity | 1.17 (better) | 0.00 |
| Net debt / EBITDA | 11.26 | – |
| Interest coverage | 3.1× | – |
| Current ratio | 1.22 | 2.75 (better) |
| Altman Z-score | 3.54 (better) | 3.20 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 113% | 86.5% |
| Held by insiders | 2.6% | 3.2% |
| Insider net buying, 12 months | −$34.8M | −$3.4M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 13.5% |
Go deeper
- LGND stock overview
- LGND income statement
- LGND valuation and score
- SDGR stock overview
- SDGR income statement
- SDGR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.